Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma

Sequential CD19- and Bcma-Specific Chimeric Antigen Receptor T Cell Treatment for RRMM: Report from a Single Center Study

(2020) Lingzhi Yan et al.   BLOOD

Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)

(2020) Deepu Madduri et al.   BLOOD

Long-Term Follow-up of a Phase 1, First-in-Human Open-Label Study of LCAR-B38M, a Structurally Differentiated Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting B-Cell Maturation Antigen (BCMA), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

(2020) Bai-Yan Wang et al.   BLOOD

A Bispecific CAR-T Cell Therapy Targeting Bcma and CD38 for Relapsed/Refractory Multiple Myeloma: Updated Results from a Phase 1 Dose-Climbing Trial

(2020) Chenggong Li et al.   BLOOD

Efficacy and Safety of Fully Human Bcma Targeting CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma

(2020) Chunrui Li et al.   BLOOD

Efficacy and Safety of Fully Human Bcma CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bcma Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma

(2020) Andrew J. Cowan et al.   BLOOD

Developing a Novel Anti-Bcma CAR-T for Relapsed or Refractory Multiple Myeloma

(2020) Xin Yao et al.   BLOOD

Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy

(2020) Jesus G. Berdeja et al.   BLOOD

B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches

(2020) Nina Shah et al.   LEUKEMIA

Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains

(2020) Norris Lam et al.   Nature Communications

Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data

(2020) Gils Roex et al.   Pharmaceutics

Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results.

(2020) Nikhil C. Munshi et al.   JOURNAL OF CLINICAL ONCOLOGY

KarMMa-RW: A study of real-world treatment patterns in heavily pretreated patients with relapsed and refractory multiple myeloma (RRMM) and comparison of outcomes to KarMMa.

(2020) Sundar Jagannath et al.   JOURNAL OF CLINICAL ONCOLOGY

BCMA-targeted immunotherapy for multiple myeloma

(2020) Bo Yu et al.   Journal of Hematology & Oncology

CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape

(2019) Mohamad Hamieh et al.   NATURE

B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma

(2019) Adam D. Cohen et al.   JOURNAL OF CLINICAL INVESTIGATION

The phase I clinical study of CART targeting BCMA with humanized alpaca-derived single-domain antibody as antigen recognition domain.

(2019) Lu Han et al.   JOURNAL OF CLINICAL ONCOLOGY

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

(2019) Noopur Raje et al.   NEW ENGLAND JOURNAL OF MEDICINE

Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma

(2019) Jie Xu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Hypoxia Selectively Impairs CAR-T Cells In Vitro

(2019) Robert Berahovich et al.   Cancers

Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen

(2019) Marijke Timmers et al.   Frontiers in Immunology

Parallel comparison of 4-1BB or CD28 co-stimulated CD19-targeted chimeric antigen receptor-T cells for B-cell non-Hodgkin lymphoma

(2019) Zhitao Ying et al.   Molecular Therapy-Oncolytics

Efficacy and Safety of CAR-T Therapy with Safety Switch Targeting Bcma for Patients with Relapsed/Refractory Multiple Myeloma in a Phase 1 Clinical Study

(2019) Weijun Fu et al.   BLOOD

T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain Induce Remissions in Patients with Relapsed Multiple Myeloma

(2019) Lekha Mikkilineni et al.   BLOOD

Phase 1 Trial of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells in Relapsed/Refractory Multiple Myeloma

(2019) Jin Jie et al.   BLOOD

Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma

(2019) Alfred L. Garfall et al.   BLOOD

Potent Anti-Tumor Activity of Bcma CAR-T Therapy Against Heavily Treated Multiple Myeloma and Dynamics of Immune Cell Subsets Using Single-Cell Mass Cytometry

(2019) Yongxian Hu et al.   BLOOD

Updated Phase 1 Results of a First-in-Human Open-Label Study of Lcar-B38M, a Structurally Differentiated Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting B-Cell Maturation Antigen (Bcma)

(2019) Lijuan Chen et al.   BLOOD

Combined Infusion of Anti-CD19 and Anti-Bcma CART Cells after Early or Later Transplantation in the Front Line Was Superior to Salvage Therapy for High Risk MM

(2019) Xiaolan Shi et al.   BLOOD

A Bcma and CD19 Bispecific CAR-T for Relapsed and Refractory Multiple Myeloma

(2019) Hua Zhang et al.   BLOOD

Chimeric antigen receptor T cell therapies for multiple myeloma

(2019) Chao Wu et al.   Journal of Hematology & Oncology

Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better?

(2019) Mattia D’Agostino et al.   LEUKEMIA

A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial

(2019) Zhiling Yan et al.   Lancet Haematology

B cell maturation antigen‐specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta‐analysis

(2019) Nico Gagelmann et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

CARs and other T cell therapies for MM: The clinical experience

(2018) Sophia Danhof et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

The Multiple Myeloma Drug Pipeline—2018: A Review of Small Molecules and Their Therapeutic Targets

(2018) Hanley N. Abramson   Clinical Lymphoma Myeloma & Leukemia

Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival

(2018) Ingemar Turesson et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma

(2018) Jennifer N. Brudno et al.   JOURNAL OF CLINICAL ONCOLOGY

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

(2018) Joseph A. Fraietta et al.   NATURE MEDICINE

Clinical and Biologic Correlates of Neurotoxicity Associated with CAR T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia (B-ALL)

(2018) Bianca D. Santomasso et al.   Cancer Discovery

bb2121 anti-BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma: Updated results from a multicenter phase I study.

(2018) Noopur S. Raje et al.   JOURNAL OF CLINICAL ONCOLOGY

Cytokine release syndrome: grading, modeling, and new therapy

(2018) Delong Liu et al.   Journal of Hematology & Oncology

Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy

(2018) Shih-Feng Cho et al.   Frontiers in Immunology

A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma

(2018) Wan-Hong Zhao et al.   Journal of Hematology & Oncology

Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma

(2018) Jinhuan Xu et al.   Journal of Hematology & Oncology

Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells

(2017) Juliane Gust et al.   Cancer Discovery

New Chimeric Antigen Receptor Design for Solid Tumors

(2017) Yuedi Wang et al.   Frontiers in Immunology

T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma

(2016) S. A. Ali et al.   BLOOD

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

(2016) Shaji Kumar et al.   LANCET ONCOLOGY

Multiple myeloma

(2015) Christoph Röllig et al.   LANCET

Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma

(2015) Alfred L. Garfall et al.   NEW ENGLAND JOURNAL OF MEDICINE

Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back

(2014) Giada Bianchi et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

(2013) Stephan A. Grupp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Multiple myeloma

(2010) M. A. Dimopoulos et al.   ANNALS OF ONCOLOGY